Issues in clinical trial design for tumor marker studies
- 1 June 2002
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (3) , 222-230
- https://doi.org/10.1053/sonc.2002.32898
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon CancerNew England Journal of Medicine, 2001
- 5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical DevelopmentInvestigational New Drugs, 2000
- Designing Tumor Marker StudiesArchives of Pathology & Laboratory Medicine, 2000
- Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trialThe Lancet, 2000
- Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patientsBritish Journal of Cancer, 2000
- Tumour markers of prognosis in colorectal cancerBritish Journal of Cancer, 1998
- The relationship between prognostic and predictive factors in the management of breast cancerBreast Cancer Research and Treatment, 1998
- Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.Journal of Clinical Oncology, 1997
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor MarkersJNCI Journal of the National Cancer Institute, 1996
- Prognostic and predictive factors for breast cancerBreast Cancer, 1995